论文部分内容阅读
应用甲氟喹750～1000mg口服剂量,治疗抗氯喹或敏感的恶性疟均获得良好效果。但在大、小白鼠的研究中,已发现伯氏疟原虫很快就可对甲氟喹产生抗性,故担心临床上单独使用也会很快产生抗药性。Fansidar按周效磺胺、乙胺嘧啶20:1的配方,作为用于抗性株的二线药,治疗急性病人和预防已经多年。在泰国及非洲国家已报告对用效磺胺、乙胺嘧啶配方的抗性程度在增加。 Fansimef采用甲氟喹250mg、周效磺胺500mg、乙胺嘧啶25mg配方(每片含量),通过这种复方剂,希望能够达到对抗性株有治疗效果,能延迟抗性出现的时间。在Ⅰ期实验中表明,对健康男
Application of mefloquine 750 ~ 1000mg oral dose, the treatment of chloroquine-resistant or susceptible to falciparum malaria have achieved good results. However, in studies of large and small mice, it has been found that Plasmodium berghei soon develops resistance to mefloquine, so it is feared that the drug will be rapidly produced in clinical use alone. Fansidar has been formulated for 20 weeks as a second-line drug for resistant strains of sulfa and pyrimethamine for the treatment of acute patients and for years of prevention. In Thailand and in Africa, there has been an increase in the resistance to sulfonamides and pyrimethamin formulations. Fansimef with mefloquine 250mg, sulfasalazine 500mg, 25mg pyrimethamine tablets (per tablet content), through this compound, hoping to have the antagonistic strains have a therapeutic effect, can delay the emergence of resistance time. In phase I experiments showed that for healthy men